All In Biotech

Drug Trial Radar · NCT07702032

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

A Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 960 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

960

Planned (sponsor's estimate)

Start

Aug 11, 2026

Primary completion

Jul 2029

Study completion Sep 2031

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Jul 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or standard-of-care cetuximab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 2 visits at the study clinic for each cycle (duration of cycle is 4 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.

Conditions

  • Left-sided Colorectal Cancer

Interventions

  • PetosemtamabDrug

    Intravenous infusion

  • CetuximabDrug

    Intravenous infusion

  • FOLFIRIDrug

    Fluorouracil + leucovorin (calcium folinate) + irinotecan via intravenous infusion.

  • mFOLFOX6Drug

    Fluorouracil + leucovorin (calcium folinate) + oxaliplatin via intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 35 months
  2. Objective Response Rate (ORR) per RECIST v1.1 as Assessed by BICRTime frame: Up to approximately 35 months

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Genesis Cancer Center

    Hot Springs, Arkansas · Recruiting

  • Valkyrie Clinical Trials - Los Angeles

    Los Angeles, California · Recruiting

  • Low Country Cancer Care Associates_Savannah_1

    Savannah, Georgia · Recruiting

  • Central Georgia Cancer Care - Warner Robins Office

    Warner Robins, Georgia · Recruiting

  • Hematology-Oncology of Indiana, P.C.

    Indianapolis, Indiana · Recruiting

  • Oncology Hematology Associates - Springfield_Springfield_2

    Springfield, Missouri · Recruiting

  • Washington University Saint Louis

    St Louis, Missouri · Recruiting

  • New York Cancer and Blood Specialists - Babylon Medical Oncology

    Babylon, New York · Recruiting

  • Vista Oncology

    Olympia, Washington · Recruiting

  • GenesisCare - Campbelltown CAMPBELLTOWN

    Campbelltown, New South Wales, Australia · Recruiting

  • GenesisCare - St Andrew's ADELAIDE

    Adelaide, South Australia, Australia · Recruiting

  • PanOncology

    Manati, PR, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.